Abstract: The present disclosure relates to the treatment of anti-PLA2R-positive membranous nephropathy. The anti-CD38 antibody, MOR202, is efficacious when administered to patients at certain dosage regimens.

Abstract: A composition comprising a CRISPR nuclease, where the nuclease includes a sequence with at least 60% sequence identity to any one of SEQ ID NOs: 143-177 and 229, optionally also including a guide nucleic acid (gNA), such as a guide ribonucleic acid (gRNA) and, in some cases, a donor sequence. Also include are methods of creating a strand break at or near a target sequence in a target polynucleotide by contacting the target polynucleotide with a nuclease including a sequence with at least 60% sequence identity to any one of SEQ ID NOs: 143-177 and 229, and a compatible guide nucleic acid (gNA), such as a guide ribonucleic acid (gRNA).

Abstract: The present invention relates to an edge connector (1) for a printed circuit board (50), comprising an at least two-part housing (10) with a first housing part (20) and a second housing part (30), wherein the first housing part (20) has a recess (25) in which at least one conductor (15) is arranged, said at least one conductor (15) having a first limb (16) with a first end (17) and a second limb (18) with a second end (19), wherein the housing (10) comprises a first region (12) in a first plane (11), in which each first end (17) protrudes out of the housing (10) in an assembly direction (5) in order to connect to a conductor track (54) of the printed circuit board (50), and the housing (10) has a second region (14) in a second plane (13) which is arranged parallel and at a distance to the first plane (11) in the assembly direction (5), wherein the second limb (18) is arranged at an angle of 90° to the first limb (16), and the second limb (18) protrudes into a mating plug recess (35) in the second housing part

Abstract: Provided herein are methods and compositions utilizing modified nucleases and/or other components, such as guide nucleic acids and donor templates, for use in a CRISPR system.

Abstract: A composition comprising a CRISPR nuclease, where the nuclease includes a sequence with at least 60% sequence identity to any one of SEQ ID NOs: 143-177 and 229, optionally also including a guide nucleic acid (gNA), such as a guide ribonucleic acid (gRNA) and, in some cases, a donor sequence. Also include are methods of creating a strand break at or near a target sequence in a target polynucleotide by contacting the target polynucleotide with a nuclease including a sequence with at least 60% sequence identity to any one of SEQ ID NOs: 143-177 and 229, and a compatible guide nucleic acid (gNA), such as a guide ribonucleic acid (gRNA).

Abstract: Provided herein are nucleic acids useful as guide nucleic acids (gNAs), e.g., guide ribonucleic acids (gRNAs), in a CRISPR system wherein the guide nucleic acids contain one or more modifications to one or more nucleotides, use of such guide nucleic acids in modifying cells, and other uses wherein CRISPR Cas proteins are utilized.

Abstract: Provided herein are nucleic acids useful as guide nucleic acids (gNAs), e.g., guide ribonucleic acids (gRNAs), in a CRISPR system wherein the guide nucleic acids contain one or more modifications to one or more nucleotides, use of such guide nucleic acids in modifying cells, and other uses wherein CRISPR Cas proteins are utilized.

Abstract: The present invention relates to an edge connector (1) for a printed circuit board (50), comprising an at least two-part housing (10) with a first housing part (20) and a second housing part (30), wherein the first housing part (20) has a recess (25) in which at least one conductor (15) is arranged, said at least one conductor (15) having a first limb (16) with a first end (17) and a second limb (18) with a second end (19), wherein the housing (10) comprises a first region (12) in a first plane (11), in which each first end (17) protrudes out of the housing (10) in an assembly direction (5) in order to connect to a conductor track (54) of the printed circuit board (50), and the housing (10) has a second region (14) in a second plane (13) which is arranged parallel and at a distance to the first plane (11) in the assembly direction (5), wherein the second limb (18) is arranged at an angle of 90° to the first limb (16), and the second limb (18) protrudes into a mating plug recess (35) in the second housing part

Abstract: The application provides an antenna element comprising a circuit board with a transmission line, the transmission line comprising at least a first conductor and a second conductor, a separate 3-dimensional, metallic or metallized ring-shaped structure mounted on a surface of the circuit board, a first galvanic contact between the first conductor and a first part of the separate 3-dimensional, metallic ring-shaped structure, and a second galvanic contact between the second conductor and a second part of the separate 3-dimensional, metallic ring-shaped structure, wherein at least one of the first galvanic contact and the second galvanic contact comprises at least two substantially L-shaped sections and an antenna array comprising several such antenna elements.

Abstract: The invention relates to methods, compositions and uses for the of treatment of cancer comprising the administration of an HDAC inhibitor as defined herein for the treatment of cancer in combination with at least one immune checkpoint modulator as defined herein.

Abstract: The present invention relates to a DYRK1B inhibitor for use in the treatment of cancer, wherein in said cancer and/or in cells of said cancer the hedgehog signaling pathway is activated, and in particular the activation of the hedgehog signaling pathway is independent of signaling by the G protein-coupled receptor Smoothened.

Abstract: The application provides an antenna element comprising a circuit board with a transmission line, the transmission line comprising at least a first conductor and a second conductor, a separate 3-dimensional, metallic or metallized ring-shaped structure mounted on a surface of the circuit board, a first galvanic contact between the first conductor and a first part of the separate 3-dimensional, metallic ring-shaped structure, and a second galvanic contact between the second conductor and a second part of the separate 3-dimensional, metallic ring-shaped structure, wherein at least one of the first galvanic contact and the second galvanic contact comprises at least two essentially substantially L-shaped sections and an antenna array comprising several such antenna elements.

Abstract: The present invention relates to a DYRK1B inhibitor for use in the treatment of cancer, wherein in said cancer and/or in cells of said cancer the hedgehog signaling pathway is activated, and in particular the activation of the hedgehog signaling pathway is independent of signaling by the G protein-coupled receptor Smoothened.

Abstract: The present invention relates to a DYRK1B inhibitor for use in the treatment of cancer, wherein in said cancer and/or in cells of said cancer the hedgehog signaling pathway is activated, and in particular the activation of the hedgehog signaling pathway is independent of signaling by the G protein-coupled receptor Smoothened.

Abstract: The present invention relates to a DYRK1B inhibitor for use in the treatment of cancer, wherein in said cancer and/or in cells of said cancer the hedgehog signaling pathway is activated, and in particular the activation of the hedgehog signaling pathway is independent of signaling by the G protein-coupled receptor Smoothened.

Abstract: The present invention relates to compounds of the general formula (I), and the pharmaceutically acceptable salt or solvate thereof, as anti-inflammatory and immunomodulatory agents.

Abstract: The present invention relates to compounds of the general formula (I) and salts and physiologically functional derivatives thereof, for the use as a medicament.

Abstract: The present invention relates to compounds of the general formula (I), and the pharmaceutically acceptable salt or solvate thereof, as anti-inflammatory and immunomodulatory agents.

Abstract: A controllable drive (1) suitable for a motor vehicle coolant pump (2) comprises a rotatably mounted shaft (5), a driven member (7) which is rotationally fixedly mounted on the shaft (5), a driving member (9) which is mounted so as to be rotatable relative to the shaft (5), and a coupling region (7/8) which is arranged between the driving and driven members (9, 7) and holds a viscous fluid. At least one first flow path and at least one second flow path connect a fluid reservoir to the coupling region (7/8), and an actuation device (11a, 11b, 12, 13, 14) changes at least one passage opening of at least one flow path. A coupling housing (8, 8a, 8b) is connected to the driving member (9), and the actuator (14) is arranged within the coupling housing (8, 8a, 8b).

Abstract: A regulatable drive for a motor vehicle, in particular for a water pump in a motor vehicle, has a rotatably mounted shaft, on which is located a rotatably mounted drive member and a rotationally fixed driven member. Between the drive member and driven member, a coupling region is defined, which can receive a viscous fluid for selectively coupling the drive member and driven member. The regulatable drive includes at least one first and at least one second flow path, which connect a fluid storage space to the coupling region, and it has a device which can be varied in its position by means of at least one actuator and which varies at least one passage orifice of at least one of the flow paths.